suppressed by further mixing a metal chloride.

Hereinafter, the examples of the present disclosure is described.

[0007a]

In one aspect, the present disclosure refers to a pharmaceutical composition for a soft contact lens, comprising 0.001 w/v% or more and 0.008 w/v% or less of an alkyldiaminoethylglycine hydrochloride and 0.3 w/v% or more and 0.8 w/v% or less of a metal chloride.

[0008]

[1] A pharmaceutical composition for a soft contact lens, comprising 0.001 w/v% or more and 0.008 w/v% or less of an alkyldiaminoethylglycine hydrochloride and a metal chloride.

[2] The pharmaceutical composition for a soft contact lens according to the above [1], comprising 0.001 w/v% or more and 0.0075 w/v% or less of the alkyldiaminoethylglycine hydrochloride.

[3] The pharmaceutical composition for a soft contact lens according to the above [1], comprising 0.001 w/v% or more and 0.005 w/v% or less of the alkyldiaminoethylglycine hydrochloride.

[4] The pharmaceutical composition for a soft contact lens according to any one of the above [1] to [3], wherein the metal chloride is one or more salts selected from the group consisting of an alkali metal chloride and a group 2 metal chloride.

[5] The pharmaceutical composition for a soft contact lens according to any one of the above [1] to [3], wherein the metal chloride is sodium chloride and/or potassium chloride.

[6] The pharmaceutical composition for a soft contact lens

according to any one of the above [1] to [5], comprising 0.05 w/v% or more and 5.0 w/v% or less of the metal chloride.

[7] The pharmaceutical composition for a soft contact lens according to any one of the above [1] to [5], comprising 0.1 w/v% or more and 2.0 w/v% or less of the metal chloride.

[8] The pharmaceutical composition for a soft contact lens

CLAIMS

1. A pharmaceutical composition for a soft contact lens, comprising 0.001 w/v% or more and 0.008 w/v% or less of an alkyldiaminoethylglycine hydrochloride and 0.3 w/v% or more and 0.8 w/v% or less of a metal chloride.

2. The pharmaceutical composition for a soft contact lens according to claim 1, wherein the metal chloride is one or more salts selected from the group consisting of an alkali metal chloride and a group 2 metal chloride.

3. The pharmaceutical composition for a soft contact lens according to claim 1, wherein the metal chloride is sodium chloride and/or potassium chloride.

4. The pharmaceutical composition for a soft contact lens according to any one of claims 1 to 3, further comprising glucose.

5. The pharmaceutical composition for a soft contact lens according to claim 4, comprising 0.001 w/v% or more and 0.01 w/v% or less of the glucose.

6. The pharmaceutical composition for a soft contact lens according to any one of claims 1 to 5, comprising 0.001 w/v% or more and 0.005 w/v% or less of the alkyldiaminoethylglycine hydrochloride.

7. The pharmaceutical composition for a soft contact lens

according to any one of claims 1 to 5, comprising:

0.001 w/v% or more and 0.005 w/v% or less of the alkyldiaminoethylglycine hydrochloride,

0.3 w/v% or more and 0.8 w/v% or less of the metal chloride, and

0.002 w/v% or more and 0.008 w/v% or less of the glucose.

8. The pharmaceutical composition for a soft contact lens according to any one of claims 1 to 7, further comprising a buffering agent.

9. The pharmaceutical composition for a soft contact lens according to claim 8, comprising 0.1 w/v% or more and 2.0 w/v% or less of the buffering agent.

10. The pharmaceutical composition for a soft contact lens according to any one of claims 1 to 9, wherein pH is 5.5 or more and 8.0 or less.

11. The pharmaceutical composition for a soft contact lens according to any one of claims 1 to 10, wherein pH is 6.5 or more and 7.5 or less.